Topoisomerase inhibitor - Idorsia
Alternative Names: TopESKAPE program-IdorsiaLatest Information Update: 01 Sep 2022
At a glance
- Originator Idorsia Pharmaceuticals
- Class Antibacterials; Bacteria; Gene therapies
- Mechanism of Action TOPORS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acinetobacter infections; Bacterial infections; Pseudomonal infections
Most Recent Events
- 31 Aug 2022 Discontinued - Preclinical for Acinetobacter infections in Switzerland (unspecified route)
- 31 Aug 2022 Discontinued - Preclinical for Bacterial infections in Switzerland (unspecified route)
- 31 Aug 2022 Discontinued - Preclinical for Pseudomonal infections in Switzerland (unspecified route)